USCIS Policy
Understanding RFE Trends in O-1A Petitions for Technology and Life Sciences Professionals in 2026
O-1A petitions for technology and life sciences professionals drew elevated RFE rates in 2026. This guide breaks down which criteria adjudicators are scrutinizing most heavily, why the documentation commonly submitted falls short, and what petition structure consistently avoids follow-up requests.
RFE patterns for technology and life sciences petitioners
USCIS O-1A petition data from the first three quarters of 2026 shows that technology and life sciences professionals continue to receive RFEs at higher rates than petitioners in many other fields. At the Nebraska Service Center, adjudicators have concentrated scrutiny on the original contributions and critical role criteria for software engineers, machine learning researchers, and biotechnology professionals. At the California Service Center, RFEs targeting the scholarly articles criterion have increased for life sciences petitioners whose publication records span clinical and basic research. Understanding which criteria draw the most scrutiny in your field and why is the necessary first step to building a petition that does not generate follow-up questions.
The technology sector creates structural difficulties for O-1A adjudication. Many technology professionals produce their most significant contributions inside proprietary systems, deployed products, or applied research that does not appear in peer-reviewed journals. An adjudicator reviewing a petition for a principal engineer or a machine learning researcher cannot evaluate a contribution by reviewing a citation database the way they can for an academic biologist. Without independent expert letters that translate the technical work into evidence of major significance, the adjudicator has no basis for finding the criterion met. Petitions that submit code repositories, internal performance metrics, or product documentation without expert corroboration consistently draw RFEs.
Life sciences petitioners face a different structural problem. Pharmaceutical development, clinical trial management, and biomedical device research are inherently collaborative, and the individual contribution can be difficult to separate from the team's output. A petition that accurately describes a clinical research program may simultaneously obscure the petitioner's specific, non-substitutable role within it. Adjudicators responding to this pattern issue RFEs asking for evidence that distinguishes the petitioner's contribution from the contributions of co-investigators, research coordinators, and institutional staff. The sections below address the four criteria where these patterns are most pronounced and describe the evidence approaches that have proved most effective.
Original contributions criterion and how adjudicators evaluate significance
The original contributions criterion under 8 C.F.R. § 214.2(o)(3)(iv)(A)(3) requires original contributions of major significance to the field. In practice, "major significance" is the phrase that drives most RFEs, because adjudicators interpret it to mean not just that a contribution was novel, but that it mattered to the field in a demonstrable way. For technology petitioners, this typically requires expert letters that explain what the contribution was, what the state of the technology was before it, and what changed in the field or industry as a direct result of the contribution. Patent records alone are insufficient — they establish novelty but not significance.
Expert letters for the original contributions criterion need to go beyond describing the work and asserting its importance. Letters that declare a contribution "groundbreaking" or "highly impactful" without explaining the mechanism of impact consistently draw RFEs. The AAO has held in multiple non-precedent decisions that conclusory expert opinions — even from credentialed experts at respected institutions — do not satisfy the evidentiary standard when they fail to connect the petitioner's specific work to identifiable downstream effects. Letters that identify specific subsequent research that built on the petitioner's contribution, or specific industry practices that changed as a result of it, are substantially more persuasive.
For life sciences petitioners, citation records are a common exhibit but a frequently misused one. Citation counts must be placed in context. A paper with 40 citations in computational biology may represent field-defining influence; 40 citations in clinical pharmacology may represent a more modest contribution. Adjudicators generally cannot assess citation significance without field-specific benchmarking. Expert letters that compare the petitioner's citation record to typical records for researchers at similar career stages and in the same subfield — using BLS SOC data or conference citation norms as reference — are far less likely to produce RFEs than raw citation exhibits submitted without interpretive context.
Critical role criterion and how adjudicators challenge it in industry settings
The critical role criterion requires that the petitioner performed in a critical or essential capacity for a distinguished organization or establishment. For technology professionals employed by established companies — major cloud service providers, pharmaceutical manufacturers, or biotechnology firms — the "distinguished organization" element is usually easy to establish. The more common RFE target is "critical or essential capacity." Adjudicators issue RFEs when a petition describes a senior role but does not specify what would have happened, or what did happen, when the petitioner's contribution was unavailable. The question adjudicators are asking is whether the petitioner's role was truly non-substitutable, not simply whether it was senior or well-compensated.
Job titles are not evidence of critical capacity. Titles like "principal engineer," "research director," or "senior scientist" appear across many roles that are professionally important but not extraordinary in the O-1A sense. What satisfies the criterion is evidence that the petitioner's specific expertise or output was necessary for a specific, significant outcome — a product launch, a clinical trial milestone, a regulatory submission, or a research publication that would not have been achieved, or would have been materially delayed or diminished, without the petitioner's work. Internal performance reviews, equity grants tied to specific deliverables, and expert letters describing the petitioner's non-substitutability at specific project junctures are more effective than general employment verification.
For life sciences petitioners, critical role evidence often centers on regulatory filings. A researcher who served as principal investigator on an IND application, contributed key findings to an NDA submission, or served as study chair on a pivotal Phase III trial has a fact pattern that can support the critical role criterion with well-documented evidence. FDA acknowledgment letters, ClinicalTrials.gov registrations listing the petitioner as principal investigator, and correspondence confirming sponsor reliance on the petitioner's specific contributions collectively establish the non-substitutable role that the criterion requires. Petitions that assemble this documentation before filing rarely receive critical role RFEs.
Scholarly articles criterion and the documentation problems it creates
The scholarly articles criterion under 8 C.F.R. § 214.2(o)(3)(iv)(A)(6) requires that the petitioner authored scholarly articles in professional journals or major trade publications. For life sciences petitioners, this criterion is typically strong — publication records in journals like Nature, Cell, the New England Journal of Medicine, JAMA, or their subfield equivalents are common. The RFEs that appear in this criterion for life sciences researchers are not usually about the quality of the journals but about the petitioner's role in multi-author publications. Adjudicators have issued RFEs asking whether a petitioner listed as a middle author on a ten-author paper made an independent scholarly contribution or functioned as a technical contributor to someone else's research program.
Technology professionals face a different version of this problem. Software engineers and machine learning practitioners often publish preprints, workshop papers, or technical blog posts that are widely read and influential within their professional communities but do not appear in refereed journals that adjudicators recognize. USCIS has historically been receptive to peer-reviewed conference proceedings publications in computer science — publications at NeurIPS, ICML, ICLR, ACL, and EMNLP, for example — but petitions sometimes fail to explain that these venues are the primary publication channel for the field and that peer review at top AI conferences is at least as rigorous as at most academic journals. Without that context, adjudicators may discount them.
Patents present a parallel documentation challenge. A granted utility patent establishes that the U.S. Patent and Trademark Office found the invention novel and non-obvious, but it does not establish scholarly contribution in the sense the criterion requires. Petitions that conflate patent records with scholarly publication records — presenting them under the scholarly articles criterion rather than the original contributions criterion — create confusion that can result in an RFE asking the petitioner to clarify which criterion the evidence is meant to support and why. Organizing exhibits precisely according to criterion, with clear headers identifying each criterion and the exhibits supporting it, will reduce this type of RFE in the record.
High salary criterion and the benchmarking disputes adjudicators raise
The high salary criterion requires that the petitioner has commanded a high salary or other significantly high remuneration relative to others in the field. For technology professionals in major metropolitan markets — New York, San Francisco, Seattle, Austin — this criterion is frequently met on paper. The RFEs that appear most often are not about the salary amount but about the benchmark used to establish it. USCIS adjudicators have rejected petitions that relied solely on general survey data without adjusting for geography, seniority level, or specialty, asking petitioners to provide comparisons that match the petitioner's specific role and location more precisely.
BLS Occupational Employment and Wage Statistics data, available by SOC code and metropolitan statistical area, is the most commonly accepted benchmark. A petition for a software engineer in the San Jose MSA should cite BLS OEWS data for SOC 15-1252 in the San Jose-Sunnyvale-Santa Clara MSA rather than national averages. The relevant threshold that most persuades adjudicators is compensation at or above the 90th percentile for the peer group — though the regulation does not specify a numerical threshold, and adjudicators have accepted cases at lower percentiles when equity compensation described in dollar terms is included in the remuneration analysis.
Life sciences petitioners often face high salary RFEs when their compensation is below 90th percentile norms for private-sector roles because they are employed in academic or nonprofit research positions. The response to this pattern is not to concede the criterion but to reframe the benchmark. A postdoctoral researcher compensated at the 85th percentile of academic researchers nationwide, with NIH grant funding providing additional programmatic resources attributable to the petitioner's role, presents a legitimate argument for the criterion that differs from how it would be analyzed for a private-sector employee. The salary exhibit must be constructed with the correct peer group — not the broadest available occupational category — to be effective.
Building an RFE-resistant petition for technology and life sciences professionals
The common thread across all four criteria discussed above is that RFEs typically arise when a petition submits documentation that would satisfy an expert reviewer but does not explain its significance to a generalist adjudicator. Expert letters are the primary mitigation tool. They should be written for the adjudicator, not the petitioner's professional community. Every letter should include a paragraph identifying the expert's own credentials, describing the field and its professional standards, explaining why those standards are the relevant benchmark for evaluating the petitioner's work, and then applying them. A letter that earns its conclusion — rather than simply asserting it — substantially reduces the likelihood of a follow-up RFE.
The organizational structure of the petition also matters. USCIS adjudicators review hundreds of petitions, and a petition that makes the adjudicator work to understand how evidence maps to criteria will generate more questions than one that does it explicitly. A well-organized O-1A petition leads with a cover letter or brief that states each criterion, cites the regulatory text, and describes the specific exhibits that support it before the exhibits appear in the record. For technology and life sciences petitioners, where the evidence is often technical and unfamiliar, the quality of the cover brief is often the difference between a petition that adjudicates cleanly and one that generates an RFE.
Premium processing under 8 C.F.R. § 103.7 is available for O-1A petitions and guarantees an adjudication decision within 15 business days. For technology professionals who are timing a job start or a transition between employers, premium processing is frequently worth the additional filing fee because it converts an uncertain eight-month timeline into a predictable one. It does not reduce the standard of review — an RFE on a premium processing petition is as detailed and time-consuming to respond to as one on a regular petition — but it ensures that the petition receives a decision quickly enough to allow a timely response and resubmission without disrupting the petitioner's employment plan.
What we typically gather for this kind of case
| Document | Where to source | Why it matters |
|---|---|---|
| Peer-reviewed publications | Web of Science / Scopus exports | Anchors original-contributions and authorship criteria |
| Citation analysis | Google Scholar profile + ESI top-1% data | Quantifies major significance in the field |
| Salary benchmark | BLS OEWS for SOC code + locality | Documents high-salary criterion at 90th-percentile or above |
| Critical-role letters | Direct supervisor + program director | Establishes role's importance, not just title |
What we see go wrong, again and again
- 01Treating extraordinary ability as a credentials checklist rather than a story of field-wide impact.
- 02Submitting bibliometric data (h-index, citation counts) without explaining what makes those numbers high relative to peers in the same sub-field.
- 03Relying on letters from collaborators or co-authors rather than independent experts who can speak to influence.
See if you qualify
Lando reviews your background against the O-1 visa criteria and tells you honestly where you stand. Free, no commitment.